November 17, 2016 - By Ellis Scott · 0 Comments
The stock of Tetralogic Pharmaceuticals Corporation (OTCMKTS:TLOG) registered a decrease of 10.68% in short interest. TLOG’s total short interest was 1.29 million shares in November as published by FINRA. Its down 10.68% from 1.44M shares, reported previously. With 190,700 shares average volume, it will take short sellers 7 days to cover their TLOG’s short positions. The short interest to Tetralogic Pharmaceuticals Corporation’s float is 7.37%. About 157,995 shares traded hands. Tetralogic Pharmaceuticals Corp (OTCMKTS:TLOG) has declined 73.64% since April 15, 2016 and is downtrending. It has underperformed by 78.26% the S&P500.
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The company has a market cap of $1.61 million. The Firm is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. It currently has negative earnings. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases.
Insitutional Activity: The institutional sentiment decreased to 0.27 in 2016 Q2. Its down 0.36, from 0.63 in 2016Q1. The ratio worsened, as 7 funds sold all Tetralogic Pharmaceuticals Corp shares owned while 4 reduced positions. 1 funds bought stakes while 2 increased positions. They now own 660,364 shares or 23.42% less from 862,305 shares in 2016Q1.
Mycio Wealth Prtn Limited Liability Com holds 0% or 12,000 shares in its portfolio. The New York-based Bank & Trust Of Mellon Corp has invested 0% in Tetralogic Pharmaceuticals Corp (OTCMKTS:TLOG). The Massachusetts-based Geode Management Limited Liability Co has invested 0% in Tetralogic Pharmaceuticals Corp (OTCMKTS:TLOG). Renaissance Limited Liability Company last reported 0% of its portfolio in the stock. Blackrock Fund Advisors has 1,931 shares for 0% of their US portfolio. Creative Planning last reported 0% of its portfolio in the stock. Manufacturers Life Ins The holds 2,672 shares or 0% of its portfolio. California Public Employees Retirement System holds 35,900 shares or 0% of its portfolio. Vanguard Grp has 0% invested in the company for 148,649 shares. Northern Tru has 0% invested in the company for 12,716 shares. Glenmede Na owns 3,925 shares or 0% of their US portfolio. Goldman Sachs Gru accumulated 0% or 41,911 shares. Gp One Trading Limited Partnership reported 3,000 shares or 0% of all its holdings. Burt Wealth Advisors, a Maryland-based fund reported 2,625 shares. Guggenheim Ltd Liability owns 21,865 shares or 0% of their US portfolio.
TetraLogic Pharmaceuticals Corporation, incorporated on October 22, 2003, is a clinical-stage biopharmaceutical company. The Firm is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Firm has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company’s histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Firm is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease resulting in the loss of hair on the scalp and elsewhere on the body. SHAPE has been granted the United States orphan drug designation for CTCL. SHAPE is a therapeutic designed to maximize HDAC inhibition locally in the skin with limited systemic exposure. The Firm is conducting Phase II clinical trial of SHAPE.
More news for Tetralogic Pharmaceuticals Corp (OTCMKTS:TLOG) were recently published by: Marketwatch.com, which released: “TetraLogic Pharmaceuticals Corp.” on August 19, 2011. Quotes.Wsj.com‘s article titled: “News TetraLogic Pharmaceuticals Corp.TLOG” and published on November 24, 2013 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ellis Scott